- Home
- PHK vs CTKB Comparison
PHK vs CTKB Comparison
Compare PHK & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHK
- CTKB
- Stock Information
- Founded
- PHK 2003
- CTKB 1990
- Country
- PHK United States
- CTKB United States
- Employees
- PHK N/A
- CTKB N/A
- Industry
- PHK Finance/Investors Services
- CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PHK Finance
- CTKB Health Care
- Exchange
- PHK Nasdaq
- CTKB Nasdaq
- Market Cap
- PHK 769.6M
- CTKB 718.8M
- IPO Year
- PHK N/A
- CTKB 2021
- Fundamental
- Price
- PHK $4.82
- CTKB $2.93
- Analyst Decision
- PHK
- CTKB Buy
- Analyst Count
- PHK 0
- CTKB 2
- Target Price
- PHK N/A
- CTKB $7.00
- AVG Volume (30 Days)
- PHK 491.5K
- CTKB 623.9K
- Earning Date
- PHK 01-01-0001
- CTKB 05-08-2025
- Dividend Yield
- PHK 12.61%
- CTKB N/A
- EPS Growth
- PHK N/A
- CTKB N/A
- EPS
- PHK N/A
- CTKB N/A
- Revenue
- PHK N/A
- CTKB $197,050,000.00
- Revenue This Year
- PHK N/A
- CTKB $4.02
- Revenue Next Year
- PHK N/A
- CTKB $8.47
- P/E Ratio
- PHK N/A
- CTKB N/A
- Revenue Growth
- PHK N/A
- CTKB N/A
- 52 Week Low
- PHK $4.13
- CTKB $3.27
- 52 Week High
- PHK $5.15
- CTKB $7.63
- Technical
- Relative Strength Index (RSI)
- PHK 59.85
- CTKB 26.81
- Support Level
- PHK $4.53
- CTKB $3.64
- Resistance Level
- PHK $4.80
- CTKB $3.89
- Average True Range (ATR)
- PHK 0.05
- CTKB 0.18
- MACD
- PHK 0.02
- CTKB -0.02
- Stochastic Oscillator
- PHK 99.64
- CTKB 5.08
About PHK Pimco High Income Fund
PIMCO High Income Fund is a closed-end management investment company. The company's primary investment objective is to seek high current income. Its secondary objective is to seek capital appreciation.
About CTKB Cytek Biosciences Inc.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.